- Home
- BIIB vs RPRX Comparison
BIIB vs RPRX Comparison
Compare BIIB & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- RPRX
- Stock Information
- Founded
- BIIB 1978
- RPRX 1996
- Country
- BIIB United States
- RPRX United States
- Employees
- BIIB N/A
- RPRX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- BIIB Health Care
- RPRX Health Care
- Exchange
- BIIB Nasdaq
- RPRX Nasdaq
- Market Cap
- BIIB 18.7B
- RPRX 16.2B
- IPO Year
- BIIB 1991
- RPRX 2020
- Fundamental
- Price
- BIIB $157.08
- RPRX $40.88
- Analyst Decision
- BIIB Buy
- RPRX Strong Buy
- Analyst Count
- BIIB 24
- RPRX 3
- Target Price
- BIIB $174.62
- RPRX $46.00
- AVG Volume (30 Days)
- BIIB 1.6M
- RPRX 2.9M
- Earning Date
- BIIB 10-30-2025
- RPRX 11-05-2025
- Dividend Yield
- BIIB N/A
- RPRX 2.16%
- EPS Growth
- BIIB N/A
- RPRX N/A
- EPS
- BIIB 10.97
- RPRX 1.60
- Revenue
- BIIB $10,065,900,000.00
- RPRX $2,349,553,000.00
- Revenue This Year
- BIIB $2.97
- RPRX $36.16
- Revenue Next Year
- BIIB N/A
- RPRX $2.04
- P/E Ratio
- BIIB $14.28
- RPRX $25.42
- Revenue Growth
- BIIB 4.77
- RPRX 3.69
- 52 Week Low
- BIIB $110.04
- RPRX $24.05
- 52 Week High
- BIIB $179.20
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- BIIB 64.92
- RPRX 75.93
- Support Level
- BIIB $148.90
- RPRX $36.03
- Resistance Level
- BIIB $155.33
- RPRX $37.40
- Average True Range (ATR)
- BIIB 4.79
- RPRX 1.11
- MACD
- BIIB 0.47
- RPRX 0.38
- Stochastic Oscillator
- BIIB 96.41
- RPRX 93.15
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.